Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 131 - 140 of 170

Selected Filters:
1 April 2022

Guidelines for PrEP Ring Pilot Implementation Studies

The intent of this document is to provide adaptable guidelines for the design of Dapivirine ring pilot implementation or post-introduction operations studies to help shape national ring guidelines.

Research, Service Delivery

Document
1 March 2022

Stakeholder conversations to inform delivery of multiple HIV prevention methods in Kenya

This report highlights findings from stakeholder conversations implemented in Kenya as part of the PROMISE Collaboration to gain input on implementation considerations for the introduction of the PrEP ring alongside oral PrEP and future inclusion of additional prevention methods for women

Research, Service Delivery

Document
15 February 2022

MTN-034 REACH

Archived from the MTN website before it was taken down. Archived MTN-034 news page also available. Primary Objectives To compare the safety profiles of FTC/TDF oral tablet administered daily and dapivirine (25 mg) vaginal matrix ring inserted once every 4 weeks during the first 24 weeks of use of each study product in an adolescent…

Research

1 February 2022

Digital Health Landscaping Report

This landscape analysis aimed to identify common virtual channels used in several countries, estimate the number of users of each channel, and categorize countries into one of three groups based on potential for interventions to use virtual channels to succeed. Users were defined as adolescent girls and young women (aged 15–24), pregnant or breastfeeding people…

Demand Creation/Marketing, Service Delivery

Document
1 November 2021

AIDS 2020 Poster – Dapivirine Ring

Poster presented at IAS 2021 attempting to estimate potential demand for the dapivirine vaginal ring across several countries in sub-Saharan Africa.

Research, Supply Chain Management

Document
1 October 2021

PrEP Ring Demand Creation Design Guide

This guide describes a step-by-step process intended to guide program teams and managers of social and behavior change programs as they design and implement an integrated demand creation strategy for the PrEP ring. The guide is not intended as a stand-alone tool. Instead, it recognizes that many tools and resources already exist to support the…

Demand Creation/Marketing

Document
1 August 2021

HIV prevention options during pregnancy and breastfeeding – what’s in the pipeline?

Slide presentation given at HIVR4P 2021 providing a broad overview of HIV prevention options for pregnant and breastfeeding populations.

Research

Document
1 May 2021

Health Care Provider Training for New HIV Prevention Products

This presentation was developed to inform the development of training curricula for new biomedical HIV prevention products. It provides summary insights from an analysis of provider training systems in Kenya, South Africa, and Zimbabwe developed for introduction of the dapivirine vaginal ring in 2020 – 2021.

Service Delivery

Document
1 March 2021

Dapivirine Vaginal Ring and Oral PrEP: Simultaneous Use Discussion

Slide presentation discussing women choosing to use both the dapivirine vaginal ring at the same time as oral PrEP — reasons for doing so, safety, ideas for future research.

Demand Creation/Marketing, Service Delivery

Document
1 February 2021

MTN-025

Archived from the MTN website before it was taken down. Primary Objectives Characterize the safety profile associated with the open-label use of the dapivirine (25 mg) vaginal matrix ring (VR) in women Characterize adherence to the open-label use of the dapivirine VR (25 mg) in women Study Summary MTN-025, the HIV Open-label Prevention Extension (HOPE)…

Research